Drug delivery in aortic valve tissue engineering

Soumen Jana, Robert D. Simari, Daniel B. Spoon, Amir Lerman

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


Over the last 50 years medicine and technology have progressed to the point where it has become commonplace to safely replace damaged or diseased heart valves with mechanical and biological prostheses. Despite the advancements in technology current valve substitutes continue to have significant limitations with regards to thrombogenicity, durability, and inability to grow or remodel. In an attempt to overcome the limitations of currently available valve prosthesis, heart valve tissue engineering has emerged as a promising technique to produce biological valve substitutes. Currently, the field of tissue engineering is focused on delivering complex matrices which include scaffolds and cells separately or together to the damaged site. Additional functional enhancement of the matrices by exposing encoded biological signals to their residing cells in a controlled manner has the potential to augment the tissue engineering approach. This review provides an overview of the delivery of biological reagents to guide and regulate heart valve tissue engineering.

Original languageEnglish (US)
Pages (from-to)307-323
Number of pages17
JournalJournal of Controlled Release
StatePublished - Dec 10 2014


  • Drug delivery
  • Fiber
  • Heart valve
  • Hydrogel
  • Scaffold
  • Tissue engineering

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Drug delivery in aortic valve tissue engineering'. Together they form a unique fingerprint.

Cite this